
|Articles|March 1, 2003
Progressing Skin Penetration
Stanford, Calif. - Conjugation of cyclosporin A to arginine oligomer protein transduction sequences provides a promising method for delivery of the peptide immunosuppressant agent into psoriatic skin. However, further study is needed to characterize the cutaneous bioavailability achieved with that novel delivery platform and to answer the larger question of whether topical cyclosporin A offers a viable therapeutic modality for psoriasis, according to David F. Fiorentino, M.D., Ph.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
5


















